Strs Ohio Invests $429,000 in Maravai LifeSciences Holdings, Inc. $MRVI

Key Points

• Strs Ohio invested $429,000 in Maravai LifeSciences Holdings, acquiring 194,000 shares and owning about 0.08% of the company as of its latest SEC filing.
• Maravai's stock price opened at $2.75, experiencing a 1.9% increase, while analysts have a consensus price target of $5.22 for the company.
• Royal Bank Of Canada recently downgraded Maravai's price objective from $7.00 to $5.00, with the stock receiving varying ratings from analysts, including three "Buy" and one "Sell" rating.

Strs Ohio acquired a new stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 194,000 shares of the company's stock, valued at approximately $429,000. Strs Ohio owned about 0.08% of Maravai LifeSciences as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. VELA Investment Management LLC raised its stake in Maravai LifeSciences by 5.6% in the 1st quarter. VELA Investment Management LLC now owns 156,334 shares of the company's stock valued at $345,000 after purchasing an additional 8,222 shares during the last quarter. Performa Ltd US LLC raised its stake in Maravai LifeSciences by 245.0% in the 1st quarter. Performa Ltd US LLC now owns 17,250 shares of the company's stock valued at $38,000 after purchasing an additional 12,250 shares during the last quarter. McAdam LLC acquired a new position in Maravai LifeSciences in the 1st quarter valued at $31,000. EntryPoint Capital LLC acquired a new position in Maravai LifeSciences in the 1st quarter valued at $32,000. Finally, Invesco Ltd. raised its stake in Maravai LifeSciences by 7.0% in the 1st quarter. Invesco Ltd. now owns 241,697 shares of the company's stock valued at $534,000 after purchasing an additional 15,751 shares during the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Stock Up 1.9%

NASDAQ MRVI opened at $2.75 on Tuesday. Maravai LifeSciences Holdings, Inc. has a 52 week low of $1.66 and a 52 week high of $8.60. The company has a quick ratio of 4.49, a current ratio of 5.16 and a debt-to-equity ratio of 0.68. The business's fifty day simple moving average is $2.50 and its 200-day simple moving average is $2.32. The firm has a market cap of $702.24 million, a PE ratio of -2.02 and a beta of 0.29.

Analysts Set New Price Targets

Separately, Royal Bank Of Canada reduced their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating for the company in a research note on Tuesday, August 12th. Three equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $5.22.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.